SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech vs. Shorts
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (165)8/17/1999 2:19:00 PM
From: rkrw  Read Replies (1) of 427
 
<You also reminded me how much I don't know about several of these companies. What's a "Hurler's race"? Sounds like an Olympic event.>

Actually, its a race to file for Fabry Disease.
It boils down to Orphan Drug Status, where one (genz or tkt) will likely be shut out of the market for 7 years. Genz ended enrollment for its pivotal trial just recently, TKT will complete its pivotal trial by year end.
So in all likelihood, as best as I can tell, TKT should be first to file.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News